PMCB (PharmaCyte Biotech) Beginning Cash Position: $15.41 Mil (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
30 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Beginning Cash Position?

PharmaCyte Biotech PMCB -0.50% 30 Beginning Cash Position is $15.41 Mil as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's Beginning Cash Position for the quarter that ended in Jan. 2026 was $15.41 Mil.

PharmaCyte Biotech's quarterly Beginning Cash Position declined from Jul. 2025 ($15.17 Mil) to Oct. 2025 ($13.18 Mil) but then increased from Oct. 2025 ($13.18 Mil) to Jan. 2026 ($15.41 Mil).

PharmaCyte Biotech's annual Beginning Cash Position declined from Apr. 2023 ($85.40 Mil) to Apr. 2024 ($68.04 Mil) and declined from Apr. 2024 ($68.04 Mil) to Apr. 2025 ($50.18 Mil).

PharmaCyte Biotech Beginning Cash Position Related Terms

PharmaCyte Biotech Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Beginning Cash Position Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 2.20 85.40 68.04 50.18

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.84 16.38 15.17 13.18 15.41
PMCB
30GF Score
PharmaCyte Biotech Inc PMCB
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $15.41 Mil mean?
PharmaCyte Biotech (PMCB) has a Beginning Cash Position of $15.41 Mil as of Jan. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Beginning Cash Position too high?
PharmaCyte Biotech's current Beginning Cash Position is $15.41 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Beginning Cash Position compare to ERNA and SYBX?
PharmaCyte Biotech's Beginning Cash Position of $15.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Beginning Cash Position is $15.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Beginning Cash Position of $15.41 Mil. The current Beginning Cash Position is $15.41 Mil. PharmaCyte Biotech's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Beginning Cash Position is $15.41 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
30GF Score

Get the complete analysis for PMCB

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price